VIA
VKTX icon

Virtus Investment Advisers’s Viking Therapeutics VKTX Stock Holding History

Virtus Investment Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Buy
11,381
+4,027
+55% +$130K 0.1% 228
2026
Q1 		$239K Buy
7,354
+180
+3% +$5.79K 0.07% 318
2025
Q4 		$252K Buy
7,174
+3,192
+80% +$113K 0.07% 323
2025
Q3 		$105K Buy
3,982
+692
+21% +$20.6K 0.03% 422
2025
Q2 		$87.2K Sell
3,290
-140
-4% -$3.69K 0.03% 395
2025
Q1 		$82.8K Buy
+3,430
New +$108K 0.02% 447

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Virtus Investment Advisers's VKTX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Viking Therapeutics (VKTX) stake by 55% in Q2 2026, buying an estimated $130K and bringing the position to 11,381 shares worth $444K. The position accounts for 0.1% of the portfolio, ranked #228.

Virtus Investment Advisers first reported a position in VKTX in Q1 2025 and has held it in 6 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Virtus Investment Advisers held 11,381 shares of Viking Therapeutics worth $444K as of Q2 2026.
  • Virtus Investment Advisers bought 4,027 Viking Therapeutics shares in Q2 2026, an estimated $130K.
  • Viking Therapeutics made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #228 holding.
  • Virtus Investment Advisers first reported a position in Viking Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.